MYndspan Unveils Crowdfunding Campaign to Broaden Access to Preventive Brain Health Solutions

Key Takeaways

MYndspan has launched a Crowdcube campaign to fund the first consumer MEG brain scanning centers, starting in London.
The technology offers real-time insights into brain function, aiding in the early detection of cognitive decline.
Investors will gain equity in MYndspan and access to innovative brain health services.

Pioneering Brain Health Accessibility

MYndspan has introduced an equity crowdfunding campaign on Crowdcube, aiming to revolutionize brain health by offering the first consumer access to clinical-grade Magnetoencephalography (MEG) brain scanning. This initiative is backed by partnerships with leading neurotechnology companies, including MEGIN and IMEDCO, and marks the launch of MYndspan’s flagship center in London.

With a mission to extend brain health diagnostics beyond traditional clinical settings, MYndspan emphasizes that MEG technology, capable of capturing brain activity in real time, can deliver critical insights into cognitive performance, neural health, and brain aging. Caitlin Baltzer, the Co-Founder and CEO, noted, “MEG is the gold standard for measuring brain function, and until now, it’s been locked away in research labs. We’re bringing it to the public.”

As cognitive decline poses a significant global health crisis, costing the economy $2.5 trillion annually, MYndspan aims to fill a vital gap in brain diagnostics. Studies suggest that up to 45% of dementia cases may be preventable with early detection, underscoring the importance of MYndspan’s capabilities in identifying early changes in brain function.

The Crowdcube campaign offers investors an opportunity to own equity in MYndspan and support its rollout across the UK. Investors will gain early access to brain scanning appointments, innovative products, and additional perks, fostering a community invested in the future of brain health. Baltzer emphasizes that this initiative is not just about investing in a company, but about investing in the future of preventive medicine.

Each MYndspan appointment combines a 10-minute non-invasive MEG brain scan with gamified assessments to evaluate cognitive functions such as attention and memory. Patients receive a personalized report within 24 hours, detailing key metrics, including brain age, connectivity, and stress levels.

To enable this breakthrough technology, MYndspan collaborates with top-tier companies in neuroimaging and clinical care. MEGIN provides industry-leading MEG systems, while IMEDCO supplies essential infrastructure. BIOS Health offers advanced neural data analysis and Re:Cognition Health integrates MYndspan’s services into existing clinical pathways for various cognitive conditions.

Baltzer states that these partnerships are crucial for scaling access to MEG technology. The campaign invites potential investors to join MYndspan in its mission to expand brain health services, highlighting its commitment to making cutting-edge diagnostics available to all.

MYndspan’s goal is to become a leading preventive health solution, promoting better brain health and enabling the early detection of neurodegenerative diseases, traumatic brain injuries, and mental health disorders.

For more information on investing in MYndspan and becoming part of this pioneering venture in brain health, please visit the official website.

The content above is a summary. For more details, see the source article.